UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063656
Receipt number R000072854
Scientific Title A Prospective Comparative Study of Clinical Outcomes and Healthcare Resource Utilization Between Hospital-at-Home and Inpatient Hospital Care Models
Date of disclosure of the study information 2026/11/18
Last modified on 2026/11/17 13:34:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Study Comparing Hospital-at-Home Care With Usual Hospitalization

Acronym

HaH study

Scientific Title

A Prospective Comparative Study of Clinical Outcomes and Healthcare Resource Utilization Between Hospital-at-Home and Inpatient Hospital Care Models

Scientific Title:Acronym

HaH study

Region

Japan


Condition

Condition

Acute medical conditions requiring hospitalization after emergency department evaluation

Classification by specialty

Emergency medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to evaluate the effectiveness, safety, feasibility, and costs of the Hospital-at-Home (HaH) early discharge model in the Japanese healthcare system by comparing it with conventional inpatient care among patients admitted under the care of the Department of Emergency Medicine at Juntendo University Urayasu Hospital.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Days Alive and at Home within 30 days (DAH30) from baseline

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Adults aged 20 years or older at the time of informed consent.
Residents of Urayasu City or Ichikawa City, or other areas where the collaborating institution can safely provide home visits.
Individuals who meet the requirements for study participation or use of information in accordance with the procedures approved by the Ethics Committee.

Key exclusion criteria

Patients who, at the time of formal eligibility assessment, require treatment in an emergency and critical care center or intensive care unit (ICU), emergency surgery, invasive procedures, continuous monitoring, or specialized treatment available only in a hospital.
Patients who are at the end of life and whose primary treatment goals are limited to end-of-life care or symptom relief rather than recovery from the acute illness.
Other patients deemed ineligible by the principal investigator for reasons related to data reliability or participant protection.

Target sample size

135


Research contact person

Name of lead principal investigator

1st name Rino
Middle name
Last name Terakawa

Organization

Juntendo Urayasu Hospital

Division name

Emergency department

Zip code

279-0021

Address

2-1-1 Tomioka, Urayasu City, Chiba, Japan

TEL

0473533111

Email

r.isogai.pv@juntendo.ac.jp


Public contact

Name of contact person

1st name Rino
Middle name
Last name Terakawa

Organization

Juntendo Urayasu Hospital

Division name

Emergency department

Zip code

279-0021

Address

2-1-1 Tomioka, Urayasu City, Chiba, Japan

TEL

0473533111

Homepage URL


Email

r.isogai.pv@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Junetendo Urayasu Hospital

Address

2-1-1 Tomioka, Urayasu City, Chiba, Japan

Tel

0473533111

Email

r.isogai.pv@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 08 Month 30 Day

Date of IRB

2026 Year 10 Month 01 Day

Anticipated trial start date

2026 Year 11 Month 18 Day

Last follow-up date

2030 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a single center prospective non randomized comparative cohort study conducted at Juntendo University Urayasu Hospital. The study will include patients admitted after evaluation in the emergency department who meet the eligibility criteria. Treatment decisions will be made as part of routine clinical practice based on the patients clinical condition medical needs preferences of the patient and family and home care environment. Patients will be classified into two groups. One group will receive the Hospital at Home early discharge model and the other group will continue conventional inpatient hospital care. Clinical outcomes and healthcare resource utilization will be compared between the two groups. No study specific therapeutic interventions or random allocation will be performed. The primary outcome is Days Alive and at Home within 30 days from baseline. The follow up period is 90 days.


Management information

Registered date

2026 Year 11 Month 17 Day

Last modified on

2026 Year 11 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072854